Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia

Cancer Discovery

Volumn 3, Issue 12, 2013, Pages 1416-1429

  Pemovska, Tea ^a   Kontro, Mika ^b   Yadav, Bhagwan ^a   Edgren, Henrik ^a   Eldfors, Samuli ^a   Szwajda, Agnieszka ^a   Almusa, Henrikki ^a   Bespalov, Maxim M ^a   Ellonen, Pekka ^a   Elonen, Erkki ^b   Gjertsen, Bjørn T ^e,f   Karjalainen, Riikka ^a   Kulesskiy, Evgeny ^a   Lagström, Sonja ^a   Lehto, Anna ^a   Lepistö, Maija ^a   Lundán, Tuija ^c   Majumder, Muntasir Mamun ^a   Marti, Jesus M Lopez ^a   Mattila, Pirkko ^a   Murumägi, Astrid ^a   Mustjoki, Satu ^b   Palva, Aino ^a   Parsons, Alun ^a   Pirttinen, Tero ^d   Rämet, Maria E ^d   Suvela, Minna ^a   Turunen, Laura ^a   Västrik, Imre ^a   Wolf, Maija ^a   Knowles, Jonathan ^a   Aittokallio, Tero ^a   Heckman, Caroline A ^a   Porkka, Kimmo ^b   Kallioniemi, Olli ^a   Wennerberg, Krister ^a   more..

^a FIMM   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF BERGEN   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALLOPURINOL; ALTRETAMINE; AMINOGLUTETHIMIDE; ANASTROZOLE; AZACITIDINE; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; EXEMESTANE; FINASTERIDE; FLUTAMIDE; FULVESTRANT; GOSERELIN; IFOSFAMIDE; LENALIDOMIDE; LETROZOLE; LOMUSTINE; MEGESTROL ACETATE; NILUTAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PIPOBROMAN; PROCARBAZINE; STREPTOZOCIN; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG REPOSITIONING; DRUG SENSITIVITY; EVALUATION AND FOLLOW UP; GENE MUTATION; HEALTH CARE PLANNING; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZED SYSTEMS MEDICINE; KARYOTYPE; ONCOLOGY WARD; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEOMICS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84890040482     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0350     Document Type: Article

References (46)

1. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-86.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
3. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-78.
4. Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
5. Dohner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011; 2011: 36-42.
6. Rowe JM, Kim HT, Tallman MS. Reply to induction therapy and outcome in acute myeloid leukemia. Cancer 2011; 117: 2237.
7. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116: 3147-56.
8. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61-9.
9. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
10. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-10.
11. Tyner JW, Yang WF, Bankhead A III, Fan G, Fletcher LB, Bryant J, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 2013; 73: 285-96.
12. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804-12.
13. Cerveira N, Correia C, Doria S, Bizarro S, Rocha P, Gomes P, et al. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 2003; 17: 2244-7.
14. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645-56.
15. Fasan A, Haferlach C, Alpermann T, Kern W, Haferlach T, Schnittger S. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Leukemia 2013; 27: 245-8.
16. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-51.
17. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010; 328: 1172-6.
18. Lannon CL, Martin MJ, Tognon CE, Jin W, Kim SJ, Sorensen PH. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. J Biol Chem 2004; 279: 6225-34.
19. Morrison KB, Tognon CE, Garnett MJ, Deal C, Sorensen PH. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene 2002; 21: 5684-95.
20. Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, et al. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 2012; 31: 1334-40.
21. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-82.
22. Borthakur G, Popplewell L, Boyiadzis M, Foran JM, Platzbecker U, Vey N, et al. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK1120212) in relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA: Georgia World Congress Center. p. 120. Abstract nr 677.
23. Gustavsson A, Olofsson T. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells. Cancer Res 1984; 44: 4648-52.
24. Larsson R, Fridborg H, Kristensen J, Sundstrom C, Nygren P. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer 1993; 67: 969-74.
25. Larsson R, Nygren P. Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. Eur J Cancer 1993; 29A: 1208-12.
26. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW, et al. I n vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-36.
27. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 2001; 15: 1892-7.
28. Iwadate Y, Fujimoto S, Namba H, Yamaura A. Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer 2003; 89: 1896-900.
29. Bosanquet AG, Bell PB. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. J Exp Ther Oncol 2004; 4: 145-54.
30. Villman K, Blomqvist C, Larsson R, Nygren P. Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer. Anticancer Drugs 2005; 16: 609-15.
31. Ehemann V, Kern MA, Breinig M, Schnabel PA, Gunawan B, Schulten HJ, et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer 2008; 122: 2719-25.
32. Lehnhardt M, Muehlberger T, Kuhnen C, Brett D, Steinau HU, Jafari HJ, et al. Feasibility of chemosensitivity testing in soft tissue sarcomas. World J Surg Oncol 2005; 3: 20.
33. Brigulova K, Cervinka M, Tosner J, Sedlakova I. Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro 2010; 24: 2108-15.
34. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-7.
35. Liu Q, Schwaller J, Kutok J, Cain D, Aster JC, Williams IR, et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 2000; 19: 1827-38.
36. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-76.
37. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732-9.
38. Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, et al. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 2011; 71: 1060-70.
39. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10.
40. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006; 22: 1540-2.
41. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-13.
42. Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S, et al. Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol 2011; 12: R94.
43. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-76.
44. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012; 6: 80-92.
45. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
46. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.